Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Bethesda, MD
Treatments:Biologic therapyHospital:Warren Grant Magnuson Clinical Center, NIH
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This Phase II study involved 72 men with hormone refractory malignant prostate cancer with bone metastases. The patients were randomly divided into two groups. Group A had 36 patients with a median age of 70.

Treatment: For Group A, the treatment consisted of one drug: ketoconazole which is an antifungal medication.

Toxicity: No grade 4-5 toxicities were observed. For Group A, grade 1-3 toxicities included fatigue, hyperglycemia, and duodenal ulcer.

Results: Group A's median survival was 19 months, while group B's median survival was not determined. However, there were no significant difference between the response rates, progression-free survival, and overall survival between Group A and Group B.

Correspondence: William D. Figg, MD





Back